Lodoxamide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Lodoxamide: From Allergic Conjunctivitis to Rosacea Conjunctivitis
One-Sentence Summary
Lodoxamide is a mast cell stabilizer, internationally known for treating vernal keratoconjunctivitis and allergic conjunctivitis, though no original indication or Canadian market data is currently on file for this drug. The TxGNN model predicts it may be effective for Rosacea Conjunctivitis, with 0 clinical trials and 0 publications currently supporting this direction — the prediction rests solely on knowledge-graph embedding similarity.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in Canadian market data (未上市); internationally known for allergic/vernal keratoconjunctivitis |
| Predicted New Indication | Rosacea Conjunctivitis |
| TxGNN Prediction Score | 98.43% |
| Evidence Level | L5 |
| Canada Market Status | ✗ Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap). Based on known information, Lodoxamide is a mast cell stabilizer; its efficacy in allergic/vernal keratoconjunctivitis has been established internationally, and mechanistically it may be applicable to other mast-cell-mediated ocular surface conditions.
Rosacea-associated conjunctivitis frequently involves a mast-cell-mediated inflammatory component, which gives the predicted link a plausible mechanistic direction — inhibiting mast cell degranulation could theoretically reduce the allergic/inflammatory contribution to ocular rosacea. However, this rationale is inferential: it draws on the general pharmacology of the mast cell stabilizer class rather than any direct evidence for rosacea conjunctivitis specifically.
Critically, the prediction is currently unsupported by any clinical trials, ICTRP registrations, or peer-reviewed literature (all evidence queries returned zero results as of 2026-03-24). The TxGNN score of 98.43% reflects graph-embedding similarity only, not validated clinical outcomes — this candidate should be read as a research hypothesis, not an evidence-backed indication.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Canada Market Information
Lodoxamide currently has no Health Canada market authorization on file (0 DINs, market status: Not Marketed). No product listings are available to summarize.
Safety Considerations
Please refer to the package insert for safety information.
Note: TFDA/Health Canada label warnings and contraindications are flagged as a Blocking data gap (DG001) — this data must be obtained before any safety pre-screening (S1) can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is based solely on TxGNN embedding similarity (Evidence Level L5) with no supporting clinical trials or literature, and the drug is not currently marketed in Canada. Combined with a Blocking-severity gap in label safety data, there is insufficient information to advance this candidate past initial screening.
To proceed, the following is needed:
- TFDA/Health Canada label data (warnings, contraindications, dosing) — currently a Blocking data gap (DG001)
- Verified mechanism of action data from DrugBank or primary literature — currently a High-severity data gap (DG002)
- Confirmation of the drug’s actual original approved indication(s), since no data is currently on file
- Preclinical or mechanistic studies specifically linking mast cell stabilization to rosacea conjunctivitis
- Ongoing literature/clinical trial surveillance, given zero hits across ClinicalTrials.gov, ICTRP, and PubMed as of the data cutoff
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.